Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: The National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI)

Cancer

Volumn 118, Issue 23, 2012, Pages 5997-6004

  Butt, Zeeshan ^a   Parikh, Neehar D ^a   Beaumont, Jennifer L ^a   Rosenbloom, Sarah K ^a   Syrjala, Karen L ^b   Abernethy, Amy P ^c   Benson, Al B ^a   Cella, David ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

advanced cancer; hepatobiliary cancer; pancreatic cancer; symptom assessment

Indexed keywords

45 ITEM FUNCTIONAL ASSESSMENT OF CANCER THERAPY HEPATOBILIARY QUESTIONNAIRE; ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CORRELATION ANALYSIS; FEMALE; FUNCTIONAL STATUS; GALLBLADDER CANCER; HUMAN; LIVER CANCER; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SYMPTOMATOLOGY; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; BILIARY TRACT NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SYMPTOM ASSESSMENT;

EID: 84869495057     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27588     Document Type: Article

References (31)

1. Benson AB 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009; 7: 350-391.
2. Tempero MA, Arnoletti JP, Behrman SW, et al. NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010; 8: 972-1017.
3. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
4. Fattovich G, Stroffolini T, Zagni I, Donato F,. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127 (5 suppl 1): S35-S50. (Pubitemid 39423368)
5. US Centers for Disease Control and Prevention. Hepatocellular carcinoma-United States, 2001-2006. MMWR Morb Mortal Wkly Rep. 2010; 59: 517-520.
6. Nordenstedt H, White DL, El-Serag HB,. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010; 42 (suppl 3): S206-S214.
7. Bruix J, Sheman M,; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020-1022.
8. Qian MY, Yuwei JR, Angus P, Schelleman T, Johnson L, Gow P,. Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital. J Gastroenterol Hepatol. 2010; 25: 951-956.
9. Yu EW, Chie WC, Chen TH,. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients? Cancer J. 2004; 10: 317-325. (Pubitemid 44403470)
10. Lang L,. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology. 2008; 134: 379. (Pubitemid 351173079)
11. Zografos GN, Farfaras A, Zagouri F, Chrysikos D, Karaliotas K,. Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreat Dis Int. 2011; 10: 10-20.
12. Rosen CB, Heimbach JK, Gores GJ,. Liver transplantation for cholangiocarcinoma. Transpl Int. 2010; 23: 692-697.
13. Yang J, Yan LN,. Current status of intrahepatic cholangiocarcinoma. World J Gastroenterol. 2008; 14: 6289-6297.
14. Shrikhande SV, Barreto SG, Singh S, Udwadia TE, Agarwal AK,. Cholelithiasis in gallbladder cancer: coincidence, cofactor, or cause! Eur J Surg Oncol. 2010; 36: 514-519.
15. Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E, Salemis NS,. Gallbladder cancer. Am J Surg. 2008; 196: 252-264. (Pubitemid 351970506)
16. Zhu AX, Hong TS, Hezel AF, Kooby DA,. Current management of gallbladder carcinoma. Oncologist. 2010; 15: 168-181.
17. Hueman MT, Vollmer CM Jr, Pawlik TM,. Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol. 2009; 16: 2101-2115.
18. Lai CH, Lau WY,. Gallbladder cancer-a comprehensive review. Surgeon. 2008; 6: 101-110.
19. Kalser MH, Barkin J, MacIntyre JM,. Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer. 1985; 56: 397-402. (Pubitemid 15031666)
20. Lim JE, Chien MW, Earle CC,. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003; 237: 74-85. (Pubitemid 36622320)
21. Nitecki SS, Sarr MG, Colby TV, van Heerden JA,. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 1995; 221: 59-66.
22. Heffernan N, Cella D, Webster K, et al. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol. 2002; 20: 2229-2239. (Pubitemid 34441650)
23. Sun V, Ferrell B, Juarez G, Wagman LD, Yen Y, Chung V,. Symptom concerns and quality of life in hepatobiliary cancers. Oncol Nurs Forum. 2008; 35: E45-E52.
24. Steel JL, Chopra K, Olek MC, Carr BI,. Health-related quality of life: Hepatocellular carcinoma, chronic liver disease, and the general population. Qual Life Res. 2007; 16: 203-215. (Pubitemid 46088354)
25. Cella D, Paul D, Yount S, et al. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest. 2003; 21: 526-535. (Pubitemid 37169556)
26. Cella D, Rosenbloom SK, Beaumont JL, et al. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. J Natl Compr Canc Netw. 2011; 9: 268-278.
27. Cella D, Butt Z, Kindler HL, et al. Validity of the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer. Eur J Cancer. Submitted for publication.
28. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570-579. (Pubitemid 23071057)
29. Yount S, Cella D, Webster K, et al. Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index. J Pain Symptom Manage. 2002; 24: 32-44.
30. US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM071975.pdf. Published December 2009. Accessed November 26, 2011.
31. McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD,. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011; 11: 163-169.